143 related articles for article (PubMed ID: 1896960)
1. Heparin cofactor II significance for the inhibition of thrombin at the injured vessel wall.
Pasche B; Swedenborg J; Frebelius S; Olsson P
Thromb Res; 1991 Jun; 62(5):409-19. PubMed ID: 1896960
[TBL] [Abstract][Full Text] [Related]
2. Depolymerized holothurian glycosaminoglycan with novel anticoagulant actions: antithrombin III- and heparin cofactor II-independent inhibition of factor X activation by factor IXa-factor VIIIa complex and heparin cofactor II-dependent inhibition of thrombin.
Nagase H; Enjyoji K; Minamiguchi K; Kitazato KT; Kitazato K; Saito H; Kato H
Blood; 1995 Mar; 85(6):1527-34. PubMed ID: 7888673
[TBL] [Abstract][Full Text] [Related]
3. Interaction of thrombin with heparin cofactor II and antithrombin III on prostacyclin production by cultured endothelial cells.
Kaji T; Itoh F; Hayakawa Y; Oguma Y; Sakuragawa N
Thromb Res; 1989 Oct; 56(1):99-107. PubMed ID: 2512688
[TBL] [Abstract][Full Text] [Related]
4. Prevention of thrombus formation and growth by antithrombin III and heparin cofactor II-dependent thrombin inhibitors: importance of heparin cofactor II.
Buchanan MR; Liao P; Smith LJ; Ofosu FA
Thromb Res; 1994 Jun; 74(5):463-75. PubMed ID: 8085247
[TBL] [Abstract][Full Text] [Related]
5. Thrombogenicity of the injured vessel wall--role of antithrombin and heparin.
Frebelius S; Hedin U; Swedenborg J
Thromb Haemost; 1994 Jan; 71(1):147-53. PubMed ID: 8165634
[TBL] [Abstract][Full Text] [Related]
6. Coagulant and noncoagulant thrombin enzymatic activity on the endothelium.
Frebelius S; Nydahl S; Swedenborg J
Blood Coagul Fibrinolysis; 1990 Aug; 1(3):285-92. PubMed ID: 2103313
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of heparin cofactor II on thrombin-stimulated prostacyclin production by cultured vascular smooth muscle cells.
Hayashi T; Kaji T; Hayakawa Y; Niiya K; Sakamoto M; Sakuragawa N
Thromb Res; 1991 Nov; 64(3):321-30. PubMed ID: 1805447
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of thrombin on subendothelium. Studies on rabbit aorta, ex vivo.
Nydahl S; Frebelius S; Swedenborg J
Eur Surg Res; 1989; 21(5):287-95. PubMed ID: 2627983
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of a thrombin anion-binding exosite-2 mutant by the glycosaminoglycan-dependent serpins protein C inhibitor and heparin cofactor II.
Cooper ST; Rezaie AR; Esmon CT; Church FC
Thromb Res; 2002 Jul; 107(1-2):67-73. PubMed ID: 12413592
[TBL] [Abstract][Full Text] [Related]
10. Significance of high levels of heparin cofactor II in the plasma and urine of adult patients with nephrotic syndrome.
Toulon P; Gandrille S; Remy P; Chadeuf G; Jouvin MH; Aiach M
Nephron; 1992; 60(2):176-80. PubMed ID: 1553002
[TBL] [Abstract][Full Text] [Related]
11. Structural features of heparin and their effect on heparin cofactor II mediated inhibition of thrombin.
Kim YS; Linhardt RJ
Thromb Res; 1989 Jan; 53(1):55-71. PubMed ID: 2922702
[TBL] [Abstract][Full Text] [Related]
12. Decreased heparin cofactor II activity is associated with impaired endothelial function determined by brachial ultrasonography and predicts cardiovascular events.
Huang PH; Leu HB; Chen JW; Wu TC; Lu TM; Yu-An Ding P; Lin SJ
Int J Cardiol; 2007 Jan; 114(2):152-8. PubMed ID: 16650906
[TBL] [Abstract][Full Text] [Related]
13. Thrombin inhibition by antithrombin III on the subendothelium is explained by the isoform AT beta.
Frebelius S; Isaksson S; Swedenborg J
Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1292-7. PubMed ID: 8857927
[TBL] [Abstract][Full Text] [Related]
14. Uptake of heparin cofactor II and antithrombin into the aorta wall after a deendothelializing injury in vivo: comparison with the behaviors of prothrombin and fibrinogen.
Hatton MW; Ross B; Southward SM; Dereske M; Hoogendoorn H; Blajchman MA; Richardson M
J Lab Clin Med; 1999 Jan; 133(1):81-7. PubMed ID: 10385486
[TBL] [Abstract][Full Text] [Related]
15. Antithrombin action of phosvitin and other phosphate-containing polyanions is mediated by heparin cofactor II.
Church FC; Pratt CW; Treanor RE; Whinna HC
FEBS Lett; 1988 Sep; 237(1-2):26-30. PubMed ID: 3169238
[TBL] [Abstract][Full Text] [Related]
16. Mutagenesis of thrombin selectively modulates inhibition by serpins heparin cofactor II and antithrombin III. Interaction with the anion-binding exosite determines heparin cofactor II specificity.
Sheehan JP; Wu Q; Tollefsen DM; Sadler JE
J Biol Chem; 1993 Feb; 268(5):3639-45. PubMed ID: 8429040
[TBL] [Abstract][Full Text] [Related]
17. Thrombin-inhibitory capacity of the injured vessel wall.
Pasche B; Swedenborg J; Hedin U; Olsson P; Ljungqvist A
Thromb Res; 1991 Jun; 62(5):531-44. PubMed ID: 1832792
[TBL] [Abstract][Full Text] [Related]
18. Role of thrombin anion-binding exosite-I in the formation of thrombin-serpin complexes.
Myles T; Church FC; Whinna HC; Monard D; Stone SR
J Biol Chem; 1998 Nov; 273(47):31203-8. PubMed ID: 9813026
[TBL] [Abstract][Full Text] [Related]
19. Selective and sustained inhibition of surface-bound thrombin activity by intimatan/heparin cofactor II and its relevance to assessing systemic anticoagulation in vivo, ex vivo and in vitro.
Buchanan MR; Maclean GA; Brister SJ
Thromb Haemost; 2001 Sep; 86(3):909-13. PubMed ID: 11583326
[TBL] [Abstract][Full Text] [Related]
20. A rationale for targeting antithrombotic therapy at the vessel wall: improved antithrombotic effect and decreased risk of bleeding.
Buchanan MR; Brister SJ
Wien Klin Wochenschr; 1999 Feb; 111(3):81-9. PubMed ID: 10093889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
